Study summary

An ultrasound implant opened the blood-brain barrier to let chemotherapy in

SonoCloud-9 trial · 33 people, phase 1/2 · Published February 2024, Nature Communications

90%of emitters opened the blood-brain barrier

What was tested

An implanted ultrasound device that temporarily opens the blood-brain barrier, combined with carboplatin chemotherapy, for recurring glioblastoma.

What they found

The barrier opened on MRI in 90% of emitter uses.
Median survival was 14.0 months from surgery; 58% were alive at 1 year.
No dose-limiting side effects.

What it means

Led to the 560-person SONOBIRD phase 3.

Nat Commun, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.